DCM
TGTX icon

DAFNA Capital Management’s TG Therapeutics TGTX Stock Holding History

DAFNA Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-75,000
Closed -$293K – 50
2013
Q4 		$293K Hold
75,000
– – 0.3% 42
2013
Q3 		$378K Buy
+75,000
New +$459K 0.41% 42

Other funds holding TGTX

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

DAFNA Capital Management's TGTX Position: Q1 2014 in Review

DAFNA Capital Management sold out of TG Therapeutics (TGTX) in Q1 2014, closing a stake of 75,000 shares — an estimated $293K sold.

DAFNA Capital Management first reported a position in TGTX in Q3 2013 and held it in 2 quarters. The position peaked at $378K in Q3 2013. 51 funds tracked by Wall St. Rank hold TGTX as of Q1 2014.

  • DAFNA Capital Management reported no remaining TG Therapeutics position as of Q1 2014 after selling out during the quarter.
  • DAFNA Capital Management sold 75,000 TG Therapeutics shares in Q1 2014, an estimated $293K.
  • DAFNA Capital Management first reported a position in TG Therapeutics in Q3 2013 and held it in 2 quarters.
  • DAFNA Capital Management's TG Therapeutics position peaked at $378K in Q3 2013.
  • 51 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2014.

Based on DAFNA Capital Management's 13F filing for Q1 2014, filed 15 May 2014.